Jade Biosciences, Inc. Common Stock

JBIONASDAQ • USD
ThemeBiotech - Drug Development›Immunology & Autoimmune
16.65 USD
↘ 0.73 (4.20%)AT CLOSE (11:59 AM EDT)
16.65
↘ 0.01 (0.03%)
POST MARKET (AS OF 07:31 PM EDT)
Post Market
AS OF 07:31 PM EDT
16.65
↘ 0.01 (0.03%)
🔴Market: CLOSED

Jade Biosciences, Inc. Common Stock (JBIO) trades at $16.63 per share. The stock presents a bearish profile across the board: technical indicators signal "Strong Sell" and our fundamental models agree with a "Sell" rating. This is driven by a robust Altman Z-Score, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bullish Golden Cross on the moving averages. Valuation metrics suggest JBIO is trading at a discount to its peers, earning an "Attractively Valued" rating.

Technical & fundamental data as of Sep 16, 2026.

Open?$17.52
High?$17.61
Low?$16.16
Prev. Close?$17.38
Volume?1.7M
Avg. Volume?843.7K
VWAP?$16.61
Rel. Volume?2.05x
Bid / Ask
Bid?$16.70 × 500
Ask?$16.92 × 100
Spread?$0.22
Midpoint?$16.81
Valuation & Ratios
Market Cap?1.1B
Shares Out?63.6M
Float?41.4M
Float %?83.9%
P/E Ratio?N/A
P/B Ratio?2.41
EPS?-$1.93
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Jade Biosciences Inc is a clinical-stage biotechnology company focused on developing therapies for autoimmune diseases. Its flagship candidate, JADE101, targets the cytokine APRIL and is in a Phase 1 clinical trial for the treatment of immunoglobulin A nephropathy. The company's pipeline also includes JADE201, an afucosylated anti-BAFF-R monoclonal antibody, and JADE301, an antibody candidate in preclinical development.
Themes
Biotech - Drug Development›Immunology & AutoimmuneBiotech - Drug Development›Rare Disease Therapeutics
Employees
55
Market Cap
1.1B
Industry
PHARMACEUTICAL PREPARATIONS
Website
www.jadebiosciences.com
Listed
2025-04-29
Address
221 CRESCENT ST.
WALTHAM, MA 02453
Phone: (781) 312-3013
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-2/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-3/3)
MA Alignment?Mixed
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
100
Momentum?
50
Short Sent.?
19
Piotroski F-Score?0/9Weak
Altman Z-Score?18.95Safe
Confidence?38%Very Low
Full Fundamental Analysis →
Short InterestSqueeze Risk
Short % of Float?24.16%Squeeze Risk
Short Interest?10.0M
Days to Cover?16.5
Free Float41.4M
Avg Daily Volume606.6K
Settlement Date2026-08-31
Financial Health
Current Ratio?14.93Strong
Quick Ratio?14.93Strong
Cash Ratio?3.40Strong
Debt/Equity?0.00Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score
100/100
P/E?
N/A▾
P/B?
Peers
100
S&P
66
2.41CHEAP▾
P/S?
N/A▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-6.0CHEAP▾
EV/Sales?
N/A▾
Returns & Efficiency
ROE?
S&P
6
-28.0%WEAK▾
ROA?
S&P
3
-26.1%WEAK▾
Cash Flow & Enterprise
FCF?$-110213000
Enterprise Value?$951.6M
Fundamentals ratios updated end of day
MarketsMoversWatchlist